Open AccessPOST-PCI CLINICAL OUTCOME;
Author(s) -
Naeem Asghar,
Muhammad Nazim,
Shakeel Ahmad
Publication year - 2017
Publication title -
the professional medical journal/the professional medical journal
Language(s) - English
Resource type - Journals
eISSN - 2071-7733
pISSN - 1024-8919
DOI - 10.29309/tpmj/2017.24.02.503
Subject(s) - medicine , conventional pci , percutaneous coronary intervention , myocardial infarction , cardiology , coronary artery disease , creatine kinase , thrombosis
The incidence of creatine kinase-myocardial band (CK-MB)isoenzyme elevation after percutaneous coronary intervention (PCI) ranges from 11% to 35%,including low-level elevations with no associated signs or symptoms as well as large non–Qwaveand Q-wave myocardial infarction. Whereas the deleterious effect on survival of largeperiprocedural myocardial infarctions have been well documented. Large periproceduralmyocardial infarctions, such as those caused by occlusion of a large side branch, flow-limitingdissection, or distal embolization of a large thrombus, would be undesirable and associatedwith worse subsequent cardiac outcomes. Objectives: To correlate the clinical outcomeafter PCI with cardiac biochemical markers. Study Design: Observational follow-up study.Setting: Faisalabad Institute of Cardiology, Faisalabad. Duration of Study with Dates: Sixmonths (February, 2014 to August, 2014). Patients and Methods: Two hundred patients withsymptoms of myocardial ischemia proceeding for percutaneous coronary intervention wereenrolled in the study. After taking history and clinical examination, the patients divided into twogroups: group I and group II. Group I comprised one hundred and fifty patients having normalcardiac enzymes and group II comprised fifty patients having raised cardiac enzymes. Results:Out of 50 patients with raised cardiac enzymes 42 (84%) were males and 8 (16%) were females,multi vessel coronary disease (58%), multi vessel PCI (54.3%). Periprocedural complicationsdissection (6%), side branch compromise (14%), slow flow (10%), no reflow (2%), sub-acutestent thrombosis (4%) occurred in group II as compared to slow flow (1.4%) and sub-acutestent thrombosis (0.7%) in group I. In hospital mortality (2%) in group II while no mortality ingroup I. On thirty day follow up 32% patients became symptomatic among which 6% developednon ST elevation MI in group II while only 1.4% patients had symptoms of angina in group I.6% patients needed repeat target lesion revascularization in group II and only 0.7% in groupI. Conclusion: Patients with raised cardiac enzymes had worse clinical outcome in terms ofmortality, myocardial infarction and repeat target lesion revascularization than normal cardiacenzymes.